Screening for Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Population Health Perspective

Sat, Nov 7, 2026 · 9:45–10:45 AM MST Convention Center: Bluebird Ballroom 2GH, Colorado Convention Center

About this session

This community conversation focuses on population health strategies for screening for fibrosis among those at risk for metabolic dysfunction–associated steatotic liver disease (MASLD). Screening for fibrosis among patients with MASLD has been recommended by hepatology, gastroenterology, and endocrinology societies but uptake has been limited.

Speaker

Meena B Bansal

Icahn School of Medicine at Mount Sinai (ISMMS)

Chair

Reviews of this session

No reviews yet

Were you in the room? Reviews are open until Nov 9, 2027.

Write the first review